Timothy Clackson
Director/Board Member at ELEVATION ONCOLOGY, INC.
Net worth: 190 267 $ as of 2024-05-30
Timothy Clackson active positions
Companies | Position | Start | End |
---|---|---|---|
ELEVATION ONCOLOGY, INC. | Director/Board Member | 2020-04-30 | - |
Independent Dir/Board Member | 2020-04-30 | - | |
IDRx, Inc.
IDRx, Inc. Miscellaneous Commercial ServicesCommercial Services IDRx, Inc. is a clinical-stage biopharmaceutical company located in an undisclosed location. The American company is dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. The company's pipeline programs include small molecule tyrosine kinase inhibitors, and idrx-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 by Alexis A. Borisy, Nicholas B. Lydon, Ben Auspitz, George D. Demetri, and Robert M. Forrester. Ben Auspitz has been the CEO since incorporation. | Chief Executive Officer | 2024-03-11 | - |
Career history of Timothy Clackson
Former positions of Timothy Clackson
Companies | Position | Start | End |
---|---|---|---|
THESEUS PHARMACEUTICALS, INC. | Director/Board Member | 2021-05-03 | 2023-12-06 |
Chief Executive Officer | 2021-05-03 | 2023-12-06 | |
President | 2021-05-03 | 2023-12-06 | |
FORMA THERAPEUTICS HOLDINGS, INC. | Director/Board Member | 2018-02-28 | 2022-10-13 |
Independent Dir/Board Member | 2018-02-28 | 2022-10-13 | |
ARIAD PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 1994-11-30 | 2017-04-30 |
THESEUS PHARMACEUTICALS, INC. | Chief Executive Officer | - | - |
XILIO THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2018-04-30 | - |
President | 2018-04-30 | - | |
FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | Director/Board Member | 2018-04-08 | - |
SPRING BANK PHARMACEUTICALS, INC. | Director/Board Member | 2018-02-28 | - |
Independent Dir/Board Member | 2018-02-28 | - | |
░░░░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Training of Timothy Clackson
University of Oxford | Undergraduate Degree |
University of Cambridge | Doctorate Degree |
Statistics
International
United States | 10 |
United Kingdom | 3 |
Operational
Director/Board Member | 6 |
Independent Dir/Board Member | 3 |
Chief Executive Officer | 3 |
Sectoral
Health Technology | 8 |
Consumer Services | 3 |
Commercial Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
XILIO THERAPEUTICS, INC. | Health Technology |
ELEVATION ONCOLOGY, INC. | Health Technology |
Private companies | 7 |
---|---|
ARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology ARIAD Pharmaceuticals, Inc. operates as an oncology company, which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company was founded by Harvey J. Berger and James E. Rothman on January 8, 1992 and is headquartered in Cambridge, MA. | Health Technology |
Massachusetts Biotechnology Council
Massachusetts Biotechnology Council Miscellaneous Commercial ServicesCommercial Services Massachusetts Biotechnology Council is a premier life sciences and healthcare hub with over 1,600 members dedicated to preventing, treating, and curing diseases through transformative science and technology. The non-profit company is based in Cambridge, MA. MassBio works to advance policy and promote education while providing member programs, events, industry information, and services. The company's mission is to advance Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system, and improve patient lives. Founded in 1985 by James P. Sherblom, the CEO is Kendalle Burlin O'Connell. | Commercial Services |
F-Star Therapeutics, Inc. (United States)
F-Star Therapeutics, Inc. (United States) Pharmaceuticals: MajorHealth Technology F-Star Therapeutics, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA. | Health Technology |
FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | Health Technology |
Forma Therapeutics Holdings, Inc.
Forma Therapeutics Holdings, Inc. Pharmaceuticals: MajorHealth Technology Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. engages in the research, development and commercialization of novel therapeutics for the treatment of hematologic diseases and cancers. Its product pipeline consists of FT-4202 for the treatment of sickle cell disease and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company was founded by Michael A. Foley in December 2011 and is headquartered in Watertown, MA. | Health Technology |
Theseus Pharmaceuticals, Inc.
Theseus Pharmaceuticals, Inc. BiotechnologyHealth Technology Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. It focuses on the discovery, development and commercialization of transformative targeted therapies. The company was founded by William C. Shakespeare, David C. Dalgarno, Iain D. Dukes, Wei Sheng Huang and Victor M. Rivera on December 29, 2017 and is headquartered in Cambridge, MA. | Health Technology |
IDRx, Inc.
IDRx, Inc. Miscellaneous Commercial ServicesCommercial Services IDRx, Inc. is a clinical-stage biopharmaceutical company located in an undisclosed location. The American company is dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. The company's pipeline programs include small molecule tyrosine kinase inhibitors, and idrx-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 by Alexis A. Borisy, Nicholas B. Lydon, Ben Auspitz, George D. Demetri, and Robert M. Forrester. Ben Auspitz has been the CEO since incorporation. | Commercial Services |
- Stock Market
- Insiders
- Timothy Clackson
- Experience